One of the most controversial topics at AbbVie's company level was whether or not the FDA would clamp down on JAK inhibitor classes due to safety concerns. Rinvoq, however, has been proven safe and effective in every study. Rinvoq, one of AbbVie's most valuable growth drugs, would be affected if the FDA imposes strict labeling. Rinvoq will replace large amounts of sales lost by Humira's patent protection in the United States.